Regeneron Pharmaceuticals

This weekend's Barron's cover story discusses why the lagging industrials could be poised for a decade of outperformance. Other featured articles discuss how American manufacturing can be reinvigorated and the coming wave of consolidation in investment management. Also, the prospects for a...

This weekend's cover story in Barron's takes a look at potential winners as the biotech industry grapples with soaring drug prices. Other featured articles offer the prospects for an apparel maker poised to rebound and a railroad-equipment supplier with global opportunities. The outlook for a...

Three big banks are among companies kicking off the new earnings season this week. Consensus forecasts from Wall Street analysts call for bottom-line declines from all three of them. However, one is expected to offer some growth in revenue, relative to the year-ago period. The second-quarter...

U.S. markets managed to squeeze out small gains in lighter than normal volume, as geopolitical tensions may be calming down. Russia President Vladimir Putin said that the country will coordinate with the International Red Cross to send humanitarian aid to Ukraine. Meanwhile, Palestinians and...

U.S. stocks declined and erased Monday's gains following reports that Russian troops were lining on the borders of Ukraine and preparing for an invasion, according to comments made by Poland's Foreign Minister. “Unfortunately, Russia has restored its combat readiness on the...

The great biotechnology sell-off of 2014 began on February 26 and started as big sell-offs often do: quietly. The SPDR S&P Biotechnology exchange-traded fund (NYSE: XBI) peaked at $172.52 and closed at $170.01, off 40 cents from the day before. The next day, the ETF finished at a record...

U.S. stocks were slightly lower as positive labor market data clashed with fourth quarter GDP estimates that showed the economic expanded less than economists had expected. Major indices finished slightly lower as the Nasdaq index continues to see its losses fall sharper compared to the Dow and...

Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...

Here's a look at the top tickers trending on StockTwits.com Regeneron: Net profit lower, sees Eylea growth This morning, Regeneron Pharmaceuticals (NASDAQ: REGN) reported its fourth quarter results. The company announced an EPS of $2.24, beating the consensus estimate of $2.08. Revenue of $...

Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...

The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates. Medivation saw its short...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages in late November. Gilead Sciences, Regeneron Pharmaceuticals, Seattle Genetics and...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD) grew by the largest percentages in late October. Biogen Idec (NASDAQ: BIIB), Illumina...

While many S&P 500 components have already shared their third-quarter results, there will be plenty more earnings reports for investors to mull over this week. The week's highlights include quarterly reports from media giants CBS, Disney and Time Warner, which all are expect to post earnings...